Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625813 | 0.88 | ATM (0.38) | ATM | |
| SCHEMBL24995617 | 0.85 | ATM (0.31) | ATM | |
| SCHEMBL14593634 | 0.79 | ATM (0.33) | ATM | |
| SCHEMBL15626511 | 0.79 | ATM (0.33) | ATM | |
| SCHEMBL23351067 | 0.74 | — | — | |
| SCHEMBL10197388 | 0.74 | CYP2D6 (0.32) | — | |
| SCHEMBL10267353 | 0.74 | CYP2D6 (0.32) | — | |
| SCHEMBL1708842 | 0.74 | CYP2D6 (0.32) | — | |
| SCHEMBL22200122 | 0.74 | ATM (0.31) | ATM | |
| SCHEMBL18387218 | 0.74 | ATM (0.34) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753642-B2 | Nucleic acids for inhibiting expression of C3 in a cell | SILENCE THERAPEUTICS GMBH (DE) | 2023-09-12 | — | — | US | disclosed |
| US-11753642-B2 | Nucleic acids for inhibiting expression of C3 in a cell | SILENCE THERAPEUTICS GMBH (DE) | 2023-09-12 | — | — | US | disclosed |
| US-20230272385-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230272385-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230024926-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11560563-B2 | SiRNAs with vinylphosphonate at the 5′ end of the antisense strand | SILENCE THERAPEUTICS GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220195436-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20220135974-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL | Universität Bern (CH) | 2022-05-05 | — | — | US | disclosed |
| US-20220017899-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | SILENCE THERAPEUTICS GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147840-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | SILENCE THERAPEUTICS GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | ATM 2131/4885 |
| US-20230272385-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | RNASE1, DCLRE1B, SNRPE | ATM 4288/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | ATM 1924/4885 |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, IAPP, INSR | ATM 2633/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | ATM 1781/4885 |
| US-20220135974-A1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL | RNASE1, SERBP1, PRSS8 | ATM 4386/4885 |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | GPR119, IAPP, INSR | ATM 2633/4885 |
| US-11560563-B2 | SiRNAs with vinylphosphonate at the 5′ end of the antisense strand | RNASE1, DCLRE1B, SNRPE | ATM 4255/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | ATM 1924/4885 |
| US-20210147840-A1 | siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND | RNASE1, DCLRE1B, SNRPE | ATM 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.